Nova Eye Medical (EYE) Discussion, page-1959

I was thinking about this.

I am not sure it is as speculative anymore.

Major risks to biotech don't apply here. We have FDA clearance and reimbursement. We have a product that is superior.

I am trying to imagine further risks but honestly it's quite hard.

The major risks before was that we weren't sure if it was going to take market share. Then sales figures showed we are at least growing rapidly.

Then it was reimbursement threats which are now gone.

The questions remaining are how much market share will they capture and can management steer the ship profitability.

I am not concerned about either of those.

Not trying to ramp, just genuinely trying to figure out why I shouldn't buy a lot more.

all imo, dyor.